Black Rock Inc. Angion Biomedica Corp. Transaction History

Black Rock Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.48 - $1.02 $855 - $1,817	1,782 Added 3.22%	57,054 $33,000
Q4 2022 Feb 13, 2023	BUY	$0.8 - $1.0 $950 - $1,188	1,188 Added 2.2%	55,272 $44,000
Q3 2022 Nov 14, 2022	SELL	$0.94 - $1.23 $1,395 - $1,826	-1,485 Reduced 2.67%	54,084 $50,000
Q2 2022 Aug 12, 2022	SELL	$1.1 - $2.23 $1.05 Million - $2.13 Million	-953,088 Reduced 94.49%	55,569 $63,000
Q1 2022 May 12, 2022	SELL	$1.72 - $2.96 $23,512 - $40,463	-13,670 Reduced 1.34%	1,008,657 $2.14 Million

Q4 2021 Feb 10, 2022	BUY	$2.35 - $9.95 $10,483 - $44,386	4,461 Added 0.44%	1,022,327 $2.96 Million
Q3 2021 Nov 09, 2021	BUY	$9.31 - $13.25 $6.86 Million - $9.76 Million	736,822 Added 262.17%	1,017,866 $9.95 Million
Q2 2021 Aug 11, 2021	BUY	$13.02 - $17.83 $3.66 Million - $5.01 Million	281,044 New	281,044 $3.66 Million

Ticker ANGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,113,300
Description
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primaril...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.